Video

Dr. Tam on Results of the CAPTIVATE Trial in CLL

Author(s):

Constantine S. Tam, MD, MBBS
Conference|ASH Annual Meeting and Exposition

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

<<< View more from the 2019 ASH Annual Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Related Content
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Urothelial Carcinoma | Image Credit: © Sebastian Kaulitzki- stock.adobe.com
December 19th 2024

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 17th 2024

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 16th 2024

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer